I do not think things are as dire as they may feel in the sector. Obviously, if the broader markets weaken (and this is traditionally a weak month), then the sector will not be able to withstand it. If you squint your eyes just right, we have actually moved higher than the previous lower high […]
August 16th Biotech Update
On a broader market perspective nothing much has changed. We really have no real momentum in either direction but I still think we have a couple of weeks of vacations before people start getting back and volume returns and we get a clearer picture of the sector sentiment or how it is going to developed […]
July 3rd Biotech Update
We at least ended the week well and while there is not a long weekend, we have the day off tomorrow for the 4th of July. I think it is going to be a slow news week and nothing too exciting in the markets. That does not mean that we cannot have a meaningful week, […]
February 15th Biotech Update
It is not the best start so far to the week but it certainly is not bad. We still have the chance to rally and I am a little encouraged by the market reaction to the hotter than expected CPI numbers. It seems to me more signals that inflation and the Fed are losing their […]
Aptose – Path Forward in 2023 With AML “Triplet Therapy”
I had a zoom meeting with Aptose’s CEO and CFO as well, to get updates regarding the new follow-up clinical trials and the timeline in 2023. The CEO was well excited with the move to the new trial in mono & combo with Venetoclax. The 1st mono therapy with 120mg (that has already started) should […]
January 3rd Biotech Update
It is a New Year and two paths diverge in the sector. One would be an unprecedented third year in a row of decline and the second would be the first up year after back to back declines. I am going to use the next couple days to delineate my predictions for 2023. LLY […]
November 15th Biotech Update
We had a nice little continuation yesterday and I would not be surprised if we do not run into a pause that refreshes (or at least it would be healthy to do so). There are a couple of different ways to think about the recent move. I would lean towards the focus on the Fed […]
September 12th Biotech Update
A strong end to last week and it would be ideal for that to continue. The forecast is a little cloudy with some good and bad news out for some big stock. We also have a little lull in the M&A and so I am not sure what impact that has had or will have […]
June 14th Biotech Update
The market is a mess. We had treasuries invert on Friday, which is a favorite signal of an impending recession. To be fair the treasury inversion over predicts recessions and so there have been many instances where nothing happened after an inversion. All that being said rising rates and high inflation is probably bound to […]
December 22nd Biotech Update
It seems to me that the sector is settling into a lull with the markets as we get to Christmas and then New Years. We managed to get out a small rally yesterday and have the chance to do it again today as we start red. While I would like to see more momentum to […]
December 6th Biotech Update
We started lower this morning which is not that bad. I think if we rallied off the start then we likely give it up but a dip to flush out the frustrated traders (and let us be honest that is all of us at this point) might clear the deck for a really rally later […]
BELLUS Health – A Fresh Look at BLU-5937 in Refractory Chronic Cough as A Phase 2b Turnaround Play
We believe this is an opportune time to revisit BELLUS Health (BLU, BLU.TO), as their Phase 2b trial results are set to be released in Q3 (interim analysis) and Q4 (Top-Line results) this year. Recall, this is a clinical stage biopharma company based in Canada (Laval) and the US (Philadelphia), developing novel medicines for the […]
June 8th Biotech Update
So I sort of missed a lot but not really. Obviously I was driving as the biggest binary in recent memory dropped but ASCO was pretty uneventful and the sector is basically still in the same range as when I left. I would hope that the BIIB news will at least get the sector to […]
Perimeter Medical Imaging AI Update – Thesis advancing to fruition
Perimeter Medical Imaging AI (PINK.v, PYNKF) is a Toronto-based company with U.S. headquarters in Dallas, Texas that is driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools. Giving physicians the ability to visualize microscopic tissue structures “real time” in the operating room has the potential to result in better long-term outcomes for patients […]
Q&A With Sarepta’s Management
It was very tight to get all my questions answered in 30 minutes, but I tried to get as much clarity as I could, let’s get straight to the questions and answers. Q: Why did you decide to expand the 103 study from 11 to 20 patients? A: To adjust the 4-5 & 6-7 years […]
March 22nd Biotech Update
A more rigorous FDA. Rising interest rates. Rising COVID cases in the EU. Lack of M&A. A lot of clinical trial failures. These are the list (probably not comprehensive) of the risks that have been used to explain the selloff in the sector. None of these have gone away and yet we still have the […]
March 11th Biotech (and Energy) Update
I think we are clearly in what sort of looks like a bottoming process but one that seems like it will be quite messy. The sector continues to be unable to generate consistently strong days but at least yesterday ended up not being a disaster. While continuation would have been great, it did not breakdown […]
March 10th Biotech Update
We obviously got a nice rebound but I would not signal the all clear yet. We have seen dead cat bounces during this pullback. I will grant that this feels different in that we rallied really strong on a day that there was negative news (another FDA CRL) and rallying on the back of bad […]
March 5th Biotech (and Energy) Report
We are in an old fashion sell off. Have we reached blood in the street/panic bottom yet? It does not quite feel like that yet but we are so oversold we could have that bounce today. If not then we are likely looking for a Tuesday reversal as markets generally do not bottom on Fridays. […]
February 8th Biotech (and MLP) Update
We have moved past the large cap portion of the earnings with positive price action in the sector but less so in the companies that are reporting. I do not believe that is related to the quality of the earnings as they were generally fine but more of a broader disconnect between large and SMID […]
